Australian (ASX) Stock Market Forum

AVH - AVITA Medical, Inc

Its nice to see it finally doing something. I bought in around 10 cents a couple of years ago when I first heard about recell. Tremendous potential...

Definitely takes a while for it to catch on but its nice to see the stock finally moving and getting some positive press.
 
Its nice to see it finally doing something. I bought in around 10 cents a couple of years ago when I first heard about recell. Tremendous potential...

Definitely takes a while for it to catch on but its nice to see the stock finally moving and getting some positive press.

Yes the new CEO has really turned the company around.

The dual listing on the OTC as well as the fact that the phase 3 trials in the US are progressing nicely has put the company on a few investors' radars.

FDA approval is looking likely to happen next year, then the SP will really head north.
 
12 months on and there's been a whole lot of not very much: SP languishing in the pre-teens

imageChart.gif

Recent shareholder update accompanying the half-year report takes an upbeat tone. I'm not familiar enough with Avita to comment yet on the figures some of which are going backwards (but for which the commentary provides explanations). Perhaps the recent mini-decline reflects disappointment?

So it all sounds upbeat, but this stock is one for the patient (sic) - on its merits one would think it would have made a lot of progress by now ...?

I disclose holdings.
 
I agree

I'm not quite sure how it hasn't gained any ground. All the studies have been positive and they had some good press. I still believe in the product. Its basically stayed in the low teens since I bought other than the slight surge a little over a year ago.

we'll see I guess
 
You always need to bear in mind that this company (with the deck chairs in the CCE position) was trading at an equivalent share price of mid $3. ie; when we received one share for the 10 (at mid 30 cents) we had.

This stock has been an absolute dog, and continues to be so.

The "new management", often used an excuse for things taking longer than expected, have been at it for over 5 years now. (CCE merger into AVH 2008).

At the end of the day, investors should consider this as being hyped up well beyond where it was ever going to go, IMO.

The AVH share price needs to rise to mid $3 just to get back to where it was, and this isn't going to happen anytime soon, by the look of it.
 
I'm not quite sure how it hasn't gained any ground.

I had looked at the chart and would be looking for a break above the 15.5. However, I didn't put it on the watchlist because I have the feeling that the market will see a cure for leg ulcers and the announcement of only the initial 3 guinea pigs as ho-hum and not "sexy" enough and look for other biotechs.

Cheers
Country Lad

avh 9 Aug 13.gif
 
The AVH share price needs to rise to mid $3 just to get back to where it was, and this isn't going to happen anytime soon, by the look of it

I really don't think that applies to someone who bought the stock at 11 cents a share. I understand you were unhappy with the merger but getting to 3 dollars would make me 5x my money so I would be pretty happy.

They are in a phase 3 trial in the us for fda approval.
 
New Life? Or preparation for a cap raising?

AVH n 21-10-15.jpg

Swing-trading while below 12c; could become a stayer if 12c breaks.
Following the recent 9.3c "gift" to Sophisticats, a similar offer to holders seems likely.
 
I've been a holder in AVH for a few months now. While I realise this has taken some years to get to this point, it seems they really are on the business end of things now. Look at the pipeline for the next 12 months, and assuming FDA approval (given they keep getting FDA approvals to increase their 'compassionate use and investigative devices' cases - i.e. approval to use in the real world without the impending FDA approval, this looks quite likely imo).

Their market cap is very low vs the market potential. SP hovering around the 10c sweet spot and no need to raise extra cash for the next 12 months if you look at their financials. To me, it seems a huge upside potential in the next 12 months with the potential for the market value of this company to increase in multiples. FDA approval will not only unleash the US market but the rest of the world too where they have already been developing sales pipelines. Downside is the risk of not getting FDA approval would be a serious blow but read through the news and judge for yourself.
 
First Fib support has been broken. I'm now looking at 7c for re-entry.

AVH i1m 05-10-17.png
 
AVH has been mostly trading between 5c and 7c during the last 12 months. However, recently an uptrend has begun to form as the share price has risen from 5c in late May to 7.5c today.

On 6 June the company announced that it had raised $16 million via an institutional placement of 320,475,665 shares at 5c. The funds were raised in preparation for the planned U.S. launch of the company's RECELL Device in the treatment of severe burns.

On 28 June AVH announced that it has entered into an agreement to acquire a manufacturing facility in Ventura, California to support the planned U.S. launch of the RECELL Device.

This morning the company released a comprehensive Corporate Presentation that explains the RECELL Device and their strategy moving forward.

With the share price holding above 7c it looks like there may be a period of consolidation at these levels while waiting for the next catalyst.

big.chart-AVH.gif
 
High volume, wider daily ranges and solid share price increases for Avita Medical over the last few trading sessions. The catalyst for the increase in activity was the announcement last Friday (21 September) that the FDA has approved AVH's RECELL® System for the treatment of severe burns in the U.S.

Things seems to be coming together nicely for AVH. The U.S. Market Launch is scheduled for the last quarter of this year and the company had this to say about it in Friday's announcement.
U.S. Market Launch

In anticipation of approval, AVITA Medical has undertaken substantial efforts to prepare for the U.S. market launch. These initiatives include the recruitment of sales and marketing leadership highly experienced in regenerative medicine and the treatment of burns, completion and assimilation of extensive direct market research, and establishment of pricing and reimbursement strategies and support infrastructure. With the receipt of FDA approval, the Company will finalize its product packaging and promotional materials to reflect the final approval details and will complete the recruitment and hiring of its field sales team. The Company expects to formally launch the RECELL System in the U.S. in the fourth calendar quarter of 2018. The Company estimates that inpatient treatment of burns in the U.S., the initial target for the RECELL System, is an approximately USD $200 million market.

Today AVH was up 35% to 13.5c, finishing the day at its high on volume of 31 million shares, the highest daily volume in 2018.

big.chart-AVH.gif
 
High volume, wider daily ranges and solid share price increases for Avita Medical over the last few trading sessions. The catalyst for the increase in activity was the announcement last Friday (21 September) that the FDA has approved AVH's RECELL® System for the treatment of severe burns in the U.S.

Solid … Nice breakout.
 
Things seems to be coming together nicely for AVH. The

Another good pickup on this one Greg ….. It showed up as a Rising Stock a few days ago. the Chart has consolidated nicely since and it looks like it could move a bit higher yet.

Around $170 million market cap and about $17 million in the bank. You still watching this one @pixel
AVH 5 Oct 2018.jpg
 
Top